Topical ciclosporin in the treatment of ocular surface disorders.
Mounting evidence suggests that inflammation is the key factor in the pathogenesis of various ocular surface diseases, with a complex interplay of genetic, environmental, and psychosocial factors. Management of these conditions is often challenging. Topical corticosteroids, with their associated side effects, are the mainstay of current treatments for patients with vision threatening disease. Ciclosporin A is an immunomodulator that specifically inhibits T lymphocyte proliferation. Recently, a topical ciclosporin preparation was approved by the US Food and Drug Administration and became available for use in ophthalmology. Given the increasing use of ciclosporin eye drops, the goal of this article is to provide the reader with an overview of the well established uses of ciclosporin and to help refine the questions that should be addressed by future investigations.
Tatlipinar
S
S
The Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, MD 21287-9238, USA.
Akpek
E K
EK
D003231:Conjunctivitis / Q000188:drug therapy; D016572:Cyclosporine / Q000627:therapeutic use*; D015352:Dry Eye Syndromes / Q000188:drug therapy; D005128:Eye Diseases / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007634:Keratitis / Q000188:drug therapy; D007637:Keratoconjunctivitis / Q000188:drug therapy; D008010:Lichen Planus / Q000188:drug therapy; D009883:Ophthalmic Solutions
D007166:Immunosuppressive Agents; D009883:Ophthalmic Solutions; D016572:Cyclosporine